Spectral domain optical coherence tomography in a patient with adult-onset vitelliform dystrophy treated with intravitreal bevacizumab

Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):319-21. doi: 10.3928/15428877-20090430-18.

Abstract

A patient with adult-onset vitelliform dystrophy received intravitreal injections of bevacizumab in one eye. During 4 months of follow-up, spectral domain optical coherence tomography (SD-OCT) showed a progressive decrease of yellowish deposits and complete resolution of subretinal fluid at the last followup. Despite the good anatomic outcome, the patient reported a mild decrease in visual acuity and persistent metamorphopsia. The clinical course and the correlation between the fundus findings and the morphologic information from SD-OCT data are described.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fourier Analysis
  • Humans
  • Injections
  • Macular Degeneration / diagnosis*
  • Macular Degeneration / drug therapy*
  • Male
  • Middle Aged
  • Tomography, Optical Coherence / methods*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab